Aditxt, Inc. (Nasdaq: ADTX), a social platform dedicated to accelerating promising health industry advancements, announced that it has signed a custody agreement with Crypto.com, a global digital asset platforms, to establish a custodial crypto account.
The agreement is a foundational step in the “broader planned rollout of bitXbio—Aditxt’s crypto-native social platform bridging Fintech and Biotech.”
Under the agreement Crypto.com will serve “as the custodian for Aditxt’s proposed digital treasury, supporting its planned strategy to back biotech innovation with a reserve of digital assets including Bitcoin.”
Additionally, ADTX common stock is now tradable “through Crypto.com’s broker-dealer, providing a more seamless opportunity for crypto native retail and institutional investors to trade ADTX.”
Crypto.com Custody, Crypto.com’s institutional-grade custody offering, “will provide the custodial services.”
Crypto.com Custody offers custody services “to eligible institutions and high-net-worth clients through a comprehensive, end-to-end solution with safety and security at its core.”
The initiative is part of Aditxt’s bitXbio platform, which “aims to expand access to innovations in immune reprogramming (Adimune), early cancer detection (Pearsanta), women’s health (Adifem) and other innovations with the potential of addressing some of the most pressing health challenges.”
Founded in 2016, Crypto.com claims it is “trusted by more than 150 million customers worldwide and is the industry leader in regulatory compliance, security and privacy.”
Their vision is: Cryptocurrency in Every Wallet.
Crypto.com is committed to accelerating the “adoption of cryptocurrency through innovation and empowering the next generation of builders, creators, and entrepreneurs to develop a fairer and more equitable digital ecosystem.”
Aditxt, Inc. is a social platform accelerating promising health advancements.
The platform is the “cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges.
Aditxt operates a model that democratizes tech advancements, “ensures every stakeholder’s voice is heard and valued, and empowers collective progress.”
The Company currently operates two programs “focused on immune health and precision health.”
Through the proposed acquisition of Evofem under the July 2024 Amended and Restated Merger Agreement between Evofem, Aditxt and Adifem, as amended, Aditxt aims “to introduce an additional program dedicated to women’s health.”
The companies are working toward a “targeted close in the second half of 2025.”
The closing of the transaction with Evofem is “subject to several conditions, including but not limited to approval of the transaction by Evofem’s shareholders and Aditxt raising sufficient capital to fund its obligations at closing.”
These obligations reportedly include “cash payments of approximately $17 million for Evofem, which includes approximately $15.2 million required to satisfy Evofem’s senior secured noteholder; should Aditxt fail to secure these funds, Evofem’s senior secured noteholder is expected to seek to prevent the closing of the merger with Evofem.”